ProCE: The Pharmacy Practice Podcast

Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:Strategies to better identify patients presenting with features of SM to facilitate timely diagnosisCurrent guideline-recommended treatment approachesEmerging data on new targeted agents for SMPharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)PresentersJonathan A. Bernstein, MDProfessor of MedicineDivision of Rheumatology, Allergy and ImmunologyDepartment of Internal MedicineUniversity of Cincinnati College of MedicinePartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center, LLCCincinnati, OhioRyan Haumschild, PharmD, MS, MBA, CPELVice President of Pharmacy, AmbulatoryEmory HealthcareWinship Cancer InstituteAtlanta, GeorgiaFull link to program page:https://bit.ly/3HcA8z2

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

In this episode, Alexa Basilio, PharmD, BCOP and Jessica Davis, PharmD, BCOP, CPP discuss immune-related adverse events and toxicities among patients using immune checkpoint inhibitors. This overview will include discussion about: How and when to monitor and treat mild vs severe immune-related toxicitiesThe art of balancing and tapering low-dose and high-dose corticosteroidsDifferentiating between immune-related and chemotherapy- or targeted therapy–associated adverse events for optimal management approachesInvolvement of multidisciplinary teams early during treatment to prevent immune-related adverse eventsImportance of educating patients, caregivers, and providers on immune-related toxicitiesPresenters: Alexa Basilio, PharmD, BCOPUniversity of Florida College of Pharmacy Oncology Pharmacy Specialist McKesson, The US Oncology NetworkTampa, Florida Jessica Davis, PharmD, BCOP, CPP Levine Cancer InstituteClinical Pharmacist Coordinator, Adult Hematology/OncologyAtrium Health Levine CenterCharlotte, North Carolina Link to full program: https://bit.ly/3We4HJy

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:Engage key stakeholders in the provision of HBV care​Provide HBV management resources to support PCPs who are doing screening​Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBVPresenters:Su Wang, MD, MPH, FACPMedical DirectorCenter for Asian Health and Viral Hepatitis ProgramsCooperman Barnabas Medical CenterRWJBarnabas-Rutgers Medical GroupAssociate MemberHealth Care Policy and Aging ResearchThe Rutgers Institute for HealthSenior AdvisorGlobal Health, Hepatitis B FoundationFlorham Park, New JerseyRichard R. Andrews, MD, MPHPresident, Houston Viral Hepatitis Task ForceFormer Co-Chair, National Task Force on Hepatitis BBoard-Certified Family MedicineAddiction Medicine PhysicianHouston, TexasRuth Brogden, MPHPatient AdvocateAmy S. Tang, MDFormer Co-Chair, National Task Force on Hepatitis BDirector of Immigrant HealthNorth East Medical ServicesSan Francisco, CaliforniaLink to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/44hXpHuGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:Patient subgroups to consider for treatment outside guideline criteriaAdverse event and cost-effectiveness considerationsIntegration of patient perspectives in wider treatmentPresenters:Mark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases, Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaJacki Chen, PhDPatient Advocate Link to full program: https://bit.ly/3TuqFHILink to the slides:https://bit.ly/4a60GM4Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:Updated CDC recommendations for one-time universal screening for HBVAddressing patient-, provider-, and system-level barriers to universal HBV screeningBest practices for implementation of HDV screeningPresenters:Douglas Dieterich, MDDirector, Institute for Liver MedicineProfessor of MedicineDivision of Liver DiseasesMount Sinai School of MedicineNew York, New YorkCamilla S. Graham, MD, MPHCo-Director, Viral Hepatitis ClinicDivision of Infectious DiseasesBeth Israel Deaconess Medical CenterHarvard Medical SchoolBoston, MassachusettsRobert Wong, MD, MS Clinical Associate ProfessorDivision of Gastroenterology and HepatologyStanford University School of MedicinePalo Alto, CaliforniaLink to full program:https://bit.ly/3TuqFHILink to the slides: https://bit.ly/4atS42z

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:Burden of CRE infections in the United StatesMechanisms of resistanceChanging epidemiologyUse of rapid diagnostic testsIDSA guidance recommendations, including supporting dataApproach to designing treatment regimens, including weighing patient- and infection-related factorsFaculty:Julie Ann Justo, PharmD, MS, FIDSA, BCPSClinical Pharmacist Lead – Infectious DiseasesInpatient PharmacyDartmouth Hitchcock Medical CenterLebanon, New HampshireLink to full program: https://bit.ly/41a8Mj0Link to accompanying ClinicalThought commentary:https://bit.ly/4865T57Link to downloadable infographic: https://bit.ly/3t7NpT2

In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman provide practical strategies for implementing RSV vaccination into practice, including: Educating older adults on RSV vaccines Providing effective, evidence-based recommendationsShared decision-making Identifying and addressing vaccine hesitancy Proactive strategies in vaccinating for RSV Predicting and overcoming barriers to RSV vaccination Presenters:Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyChristina M. Madison, PharmD, FCCP, AAHIVPClinical PharmacistFounder and CEO, The Public Health Pharmacist, PLLCAdjunct Associate Professor of Pharmacy PracticeRoseman University of Health SciencesCollege of PharmacyHenderson, NevadaOther program activities: Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist's Role https://bit.ly/49GUv1gLink to CME: Claim Credit – https://bit.ly/3uoY7VH[After selecting the “Continue to Post Test” button:]To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.

In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman discuss the latest practical strategies for preventing RSV infection in older adults, including: Role of basic public health precautionsAvailable and emerging vaccinesMechanisms of action, therapeutic targets, and pharmacologyEfficacy and safety dataFDA approval status and ACIP recommendationsPresenters:  Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyChristina M. Madison, PharmD, FCCP, AAHIVP  Clinical PharmacistFounder and CEO, The Public Health Pharmacist, PLLCAdjunct Associate Professor of Pharmacy PracticeRoseman University of Health SciencesCollege of PharmacyHenderson, NevadaOther program activities:  • Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist's Role     

In this accredited podcast episode, Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP, discusses the most important things for pharmacists across all settings to know about RSV infections in patients 60 years of age or older, including: Incidence and prevalence of RSV in older adults, including hospitalization, mortality, epidemiologySeasonalityClinical manifestationsRisk factors for severe outcomesVulnerable groups and comorbiditiesPresenter:Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyOther program activities: Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist's Role https://bit.ly/49GUv1gLink to CME: Claim Credit – https://bit.ly/47GtNnK[After selecting the “Continue to Post Test” button:]To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.

In this episode, Sarah Hayward, PharmD, BCOP, and Amy Ly Indorf, PharmD, BCOP, discuss their experiences providing care for patients with advanced ovarian cancer, with topics including:PARP inhibitors as frontline maintenance therapyPatient education and counseling on PARP inhibitorsHelping patients access newer therapiesExperiences with mirvetuximab soravtansinePatient education and counseling on mirvetuximab soravtansineTreatment modalities on the horizon Presenters:Sarah Hayward, PharmD, BCOPClinical Pharmacy Specialist,Gynecologic OncologyStephenson Cancer Center atOU HealthOklahoma City, OklahomaAmy Ly Indorf, PharmD, BCOPClinical Assistant ProfessorUniversity of Washington School of PharmacyClinical Oncology PharmacistUW MedicineFred Hutchinson Cancer CenterSeattle, WashingtonSupported by educational grants from GSK and Novocure, Inc.Link to full program:https://bit.ly/44fUiOU 

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:Current COVID-19 landscapeRapid antigen tests and PCR testsRisk stratification of patients who have a positive SARS-CoV-2 testAntiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)Long COVIDPresenters:Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTrinh P. Vu, PharmD, BCIDPClinical Pharmacy Specialist in Infectious DiseasesDepartment of Pharmaceutical ServicesEmory University Hospital MidtownAtlanta, GeorgiaTo download the slides: bit.ly/3oHKC09To view the full online program: bit.ly/4201xcO

In this episode, pharmacists Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM, and Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, discuss the use of GLP-1 receptor agonists in patients with type 2 diabetes and provide answers to commonly asked questions. Listen to their conversation about the differences between short-acting vs long-acting agents; the benefits of use in combination with other medications, such as SGLT2 inhibitors, DPP-4 inhibitors, and metformin; their benefits in heart failure; and their role in the updated consensus statement from the American Diabetes Association/European Association for the Study of Diabetes. Presenters:Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADMClinical ProfessorDepartment of Pharmacy PracticeAuburn University Harrison College of PharmacyClinical PharmacistBaptist Health Foundation Center for Medical and Surgical CarePrinceton Baptist Medical Center/Brookwood Baptist HealthBirmingham, AlabamaChristie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessorDepartment of Pharmacy PracticeMidwestern UniversityCollege of PharmacyDowners Grove, IllinoisClinical PharmacistAdvocate Medical GroupChicago, IllinoisContent based on an online CE program supported by an educational grant from Novo Nordisk, Inc.Link to full program: https://bit.ly/3Un1xQi

In this episode, Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, discuss the use of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes, including:Overview of chronic kidney diseaseGuideline recommendationsEvidence for finerenoneRole of the pharmacistPresenter:Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCPEndocrine Clinical Pharmacy SpecialistCGM and Remote Monitoring Program CoordinatorEndocrinology and Metabolism InstituteCleveland ClinicCleveland, OhioJoshua J. Neumiller, PharmD, CDCES, FADCES, FASCPVice Chair and Allen I. White Distinguished ProfessorDepartment of PharmacotherapyCollege of Pharmacy and Pharmaceutical Sciences  Washington State UniversitySpokane, WashingtonReview the downloadable slideset and the full program at:https://bit.ly/3wxNAod

This podcast is the third in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, pharmacist Kathleen A. Lusk, PharmD, BCPS, BCCP, provides an overview of health disparities, patient engagement, and collaborative team-based care to optimize outcomes for patients with NVAF. Dr Lusk reviews best practices in using the principles of motivational interviewing to employ shared decision-making and models these strategies with 2 simulated clinical patient visits. Common barriers, such as medication access and adherence, also are discussed, along with practical solutions for overcoming these care obstacles. Presenter:Kathleen A. Lusk, PharmD, BCPS, BCCPAssociate Professor and Vice ChairDepartment of Pharmacy PracticeUniversity of the Incarnate Word Feik School of Pharmacy Adjunct Assistant ProfessorClinical Pharmacy SpecialistDivision of CardiologyDepartment of MedicineUT Health San AntonioSan Antonio, TexasContent is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to:https://bit.ly/3OMazV8

This podcast is the first in a series of three featuring cardiology pharmacists Kathleen A. Lusk, PharmD, BCPS, BCCP, and Stephanie Dwyer Kaluzna, PharmD, BCCP. In this episode, Drs Lusk and Dwyer Kaluzna provide an overview of nonvalvular atrial fibrillation (NVAF), including prevalence, burden, and consequences of undiagnosed NVAF and the role of pharmacists in screening for the condition in various pharmacy settings.Presenters:Kathleen A. Lusk, PharmD, BCPS, BCCP  Associate Professor and Vice Chair  Department of Pharmacy PracticeUniversity of the Incarnate Word Feik School of Pharmacy  Adjunct Assistant ProfessorClinical Pharmacy SpecialistDivision of CardiologyDepartment of MedicineUT Health San AntonioSan Antonio, TexasStephanie Dwyer Kaluzna, PharmD, BCCP  Clinical Assistant ProfessorDepartment of Pharmacy PracticeUniversity of Illinois Chicago College of PharmacyCardiovascular Clinical PharmacistUniversity of Illinois Hospital and Health Science SystemChicago, IllinoisContent is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go tohttps://bit.ly/3OMazV8

This podcast is the second in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, cardiology pharmacist Stephanie Dwyer Kaluzna, PharmD, BCCP, reviews key literature and guideline recommendations for stroke prevention in patients with NVAF. Dr Dwyer Kaluzna discusses the most recent evidence for prescribing, dosing, and monitoring direct oral anticoagulants (DOACs); using the risk-screening tools HAS-BLED and CHA2DS2-VASc to design patient-specific pharmacotherapy plans; and the use of DOACs in special patient populations, including older patients, patients with end-stage renal disease, and patients with low or high body weights.Presenter:Stephanie Dwyer Kaluzna, PharmD, BCCP  Clinical Assistant ProfessorDepartment of Pharmacy PracticeUniversity of Illinois Chicago College of PharmacyCardiovascular Clinical PharmacistUniversity of Illinois Hospital and Health Science SystemChicago, IllinoisContent is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance.This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go tohttps://bit.ly/3OMazV8

In this episode, pharmacists Megan Adelman, PharmD, BCPS, BCGP, CDCES, and Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA, provide an overview of obesity, including pathophysiology and the benefits of long-term weight loss, and discuss guideline recommendations for treatment, pharmacotherapy options including injectable agents, and overcoming barriers to care.Presenters:Megan Adelman, PharmD, BCPS, BCGP, CDCESFamily Medicine Clinical SpecialistCenter for Family MedicineCleveland Clinic Akron GeneralAkron, OhioElizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPAProfessorDepartment of Pharmacy PracticeCollege of Pharmacy-GlendaleMidwestern UniversityGlendale, ArizonaContent based on an online CE program supported by an educational grant from Novo Nordisk, Inc.Link to full program:https://bit.ly/3EAARVu

FacultyTyree H. Kiser, PharmD, FCCM, FCCP, BCCCP, BCPSProfessor, Department of Clinical PharmacyUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesCritical Care Pharmacy Specialist, Department of PharmacyUniversity of Colorado HospitalAurora, ColoradoCharles E. “Kurt” Mahan, PharmD, PhC, FASHP, FCCPAdjunct Associate Professor, PharmacyUniversity of New Mexico Health Sciences CenterAlbuquerque, New Mexico  Content based on a CE activity supported by an educational grant from Alexion, AstraZeneca Rare Disease.  Link to full activity: https://www.proce.com/Anticoagulation

1:08 - Take-home thoughts for R/R MM 3:47 - Summary of BCMA-targeted CAR T-cell therapy; Use of novel agents for R/R MM6:47 - Information on melphalan flufenamide; Combination approaches with selinexor in clinical practice9:59 - Cost considerations for treatment options in R/R MM12:25 - Administration considerations for subcutaneous daratumumab and venetoclax in R/R MMFacultyKathryn Maples, PharmD, BCOPClinical Pharmacy Specialist, Multiple MyelomaWinship Cancer Institute, Emory HealthcareAtlanta, GeorgiaTim Peterson, PharmD, BCOPClinical Pharmacy Specialist – Multiple MyelomaMemorial Sloan Kettering Cancer CenterNew York, New York Content based on a CE activity supported by educational grants from Karyopharm Therapeutics, Inc. and Oncopeptides, Inc.Link to full activity: https://www.proce.com/RRMM